Scadenza: 29 September 2020
Scadenze successive:
17 March 2021
Topic:
Topic 1: Returning clinical trial data to study participants within a GDPR compliant and approved ethical framework
Topic 2: Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
Topic 3: A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
Topic 4: Optimal treatment for patients with solid tumours in Europe through artificial intelligence
Topic 5 Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies
Topic 6: Behavioural model of factors affecting patient adherence
Programma:
Innovative Medicines Initiative (IMI2)
Ente finanziatore:
European Commission and European Federation of Pharmaceutical Industries and Associations (EFPIA)
Budget complessivo:
95 MLN
Who can participate:
H2020 participation rules:
a) at least three legal entities shall participate in an action;
b) three legal entities shall each be established in a different Member State or associated country;
c) the three legal entities referred to in point (b) shall be independent of each other.
Partnership: Mandatory
Status:
Closed
Topic:
Topic 1: Returning clinical trial data to study participants within a GDPR compliant and approved ethical framework
Topic 2: Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
Topic 3: A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
Topic 4: Optimal treatment for patients with solid tumours in Europe through artificial intelligence
Topic 5 Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies
Topic 6: Behavioural model of factors affecting patient adherence
Who can participate:
H2020 participation rules:
a) at least three legal entities shall participate in an action;
b) three legal entities shall each be established in a different Member State or associated country;
c) the three legal entities referred to in point (b) shall be independent of each other.
Programme:
Innovative Medicines Initiative (IMI2)
Consortium: Required
Status: Open
Total budget:
95 MLN
Funding rate:
